PDL BioPharma Inc

PDL BioPharma — Investor Presentation (July 2020)

30 slides from PDL BioPharma's investor presentation, Jul 17, 2020

  1. Slide 1: Management Presentation July 2020

    ee i | LENSAR MANAGEMENT PRESENTATION JULY 2020 we |

  2. Slide 2: Disclaimer

    Disclaimer This presentation information contained in these materials has been provided by LENSAR, Inc. (the “Company”, “we” or “our”). No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the in

  3. Slide 3: Investment Highlights

    Investment Highlights Leading Innovator of Femtosecond Cataract Lasers (FLS) ina Growing Cataract Surgery Market * Innovation Leader: Proprietary laser system leads the market in innovation * Disruptive Technology Platform: — Commercially available Streamline® IV - enables optimal treatment of tissu

  4. Slide 4: Cataract is Highest Volume Surgical Procedure Worldwide

    _ Cataract is Highest Volume Surgical Procedure Worldwide 29 Million global cataract/refractive lens exchange surgical procedures in 2019 Cataract Procedure Breakdown ECCE/Other Ultrasonic Phacoemulsification (USP) 2024 FLACS forecast in cataract/refractive lens exchange procedures is 1 million 2024

  5. Slide 5: Visually Significant Astigmatism Exists in the Majority of People

    Visually Significant Astigmatism Exists in the Majority of People Who Need Cataract Surgery but Remains Uncorrected") Post-Cataract Surgery with Post-Cataract Surgery Pre-Cataract Surge! gery Visually Significant Astigmatism With Astigmatism Corrected “a “ ; * = —_ + Glasses donothelpvision + Glasse

  6. Slide 6: Femtosecond Laser Assisted Cataract Surgery (FLACS) Still Underpenetrated

    Femtosecond Laser Assisted Cataract Surgery (FLACS) Still Underpenetrated Worldwide . 2019 Procedure Cataract/RLE * Global market penetration World Region Installations (FLACS procedures) grew to 13% in 2019 United States 1,568 473,536 10.7% * FLACS procedures expected to grow Wester Europe Bet 90,2

  7. Slide 7: Growth Drivers of FLACS Market

    Growth Drivers of FLACS Market * Increase in premium procedures * Increased penetration of premium procedures — Driven by clinical evidence of improved outcomes * Emergence of PE-backed ophthalmology groups that can afford lasers and actively seeking ways to increase revenue * Next Gen devices that

  8. Slide 8: Summary of LENSAR's Differentiation

    Summary of LENSAR’s Differentiation IntelliAxis Refractive Capsulorhexis® Wireless Transfer of Pre-Op Diagnostic Data 4 Iris Registration and Autom: Cataract Density Imaging Highly Efficient Custom Fragmentation

  9. Slide 9: Surgeon-Designed Ergonomics Fits Seamlessly Into Multi-Environments

    Surgeon-Designed Ergonomics Fits Seamlessly Into Multi-Environments + Multiple touch screens provide visibility for surgeon, scrub and circulating nurse + Allows use ina sterile or non-sterile environment » Retracting laser head allows unrestricted access to the treated eye after the laser procedure

  10. Slide 10: Cataract Density Imaging

    Cataract Density Imaging Category 1 Cataract Density Imaging: Category 2 We believe only LENSAR automatically categorizes the density of each cataract and determines the location of the nucleus to increase treatment efficiency and potentially decrease Category 3 laser energy used in the eye. LENSAR

  11. Slide 11: IntelliAxis Refractive Capsulorhexis to Guide Toric IOL Alignment

    IntelliAxis Refractive Capsulorhexis® to Guide Toric lOL Alignment + WiFi integration with leading diagnostics equipment + Adjusts for cyclorotation, precisely places Toric IOL on the desired axis — visualize intra and post operatively + Facilitates and optimizes IOL alignment along the pre-defined

  12. Slide 12: LENSAR with Streamline Iris Registration

    LENSAR with Streamline™ Iris Registration + Iris Registration eliminates the need to manually mark the cornea * Reduces or eliminates transcription and marking errors » In this example, there was a 9.5° clockwise rotation that was detected and compensated during the incision planning phase of the pr

  13. Slide 13: Essence of LENSAR's Differentiation

    Essence of LENSAR’s Differentiation IntelliAxis Refractive Capsulorhexis® - Unique and Proprietary Technology IntelliAxis Refractive Capsulorhexis®... * Creates a pair of small tabs on the capsular rim guided by Iris Registration to identify the intended axis as part of the laser Refractive Capsulor

  14. Slide 14: The Surgeon's Perspective on LENSAR Technology

    The Surgeon’s Perspective on LENSAR Technology “What | enjoy is the refractive outcomes and the predictability that the LENSAR® Laser System now affords me as it relates to astigmatism correction with toric IOL placement. The IntelliAxis Refractive Capsulorhexis® places refractive marks on the capsu

  15. Slide 15: Unmet Need and Room for Improvement

    Unmet Need and Room for Improvement Spectacle-independence must include management of astigmatism Number of Patients Prevalence of igmatism Prior to Cataract Surgery 70-90% of patients have treatable astigmatism; the majority of these remain uncorrected* 19.1% 1800 1350 17.196} Aa N=6,000 1200 ‘Warr

  16. Slide 16: Disruptive Astigmatism Management Capability

    Disruptive Astigmatism Management Capability Current solutions are sub-optimal; for 50% of pre-existing, no attempt to treat LASIK, PRK — Significant contraindications (dry-eye), flaps — Secondary procedures take additional patient and surgeon time, visual recovery time, added cost Al incisions (man

  17. Slide 17: LENSAR: Tools to Enable Superior Outcomes

    LENSAR: Tools to Enable Superior Outcomes P< 0001 ao 15D Fhe-op Mean Reve (jade: Pastp Men Rev (inde (w= 60) (W=60) 0 02 oo - P0001 ono FreopMeon aot Cyider Fstop Mean Reka Ginder ) ce) r 1010 Postoperative Results + 98% of eyes with toric IOL treatment were <0.5 D + Oeyes had IOL misalignment or ad

  18. Slide 18: wer 81,085

    * $08,030 ro" ] & no wer 81,085 63,175 49,769 38,528 2015 216 2017 218 2019

  19. Slide 19: LENSAR Laser Utilization Significantly Higher than Other Femto Systems

    LENSAR Laser Utilization Significantly Higher than Other Femto Systems Procedure volume grew 30% YOY since 2016 Avg. per LENSAR Avg. Comparison to World Region Installed Device!) | Procedures per Laser Industry Average LENSAR installed systems | 610 Uaiadl Seated 302 0088 performed 79% more procedur

  20. Slide 20: ALLY — All-in-One Femto Phaco Device

    ALLY™ — All-in-One Femto Phaco Device We are developing a compact, integrated workstation with state-of-the-art attributes of a LENSAR system AND a phacoemulsification system Anticipated benefits of our design: * Easily replace older technology — Configured anywhere in the operating room; increasing

  21. Slide 21: ALLY — Phaco / Industrial Design

    ALLY™ — Phaco / Industrial Design Latest ALLY™ Working Prototype: ALLY™ Industrial Design: 24

  22. Slide 22: Summary of Key Findings: LENSAR ALLY Third Party US Physician Survey

    Summary of Key Findings: LENSAR ALLY™ Third Party US Physician Survey Market Research Project Overview * Third party survey with results from 122 US cataract surgeons to assess perceptions regarding FLACS and LENSAR ALLY™ product concept, to inform ALLY™ revenue forecast Key Findings « 40% said that

  23. Slide 23: Revenue Growth; R&D Investment in 2019 Driven by ALLY

    ng Revenue Growth; R&D Investment in 2019 Driven by ALLY™ Annual 2018 2019 Revenue $24.4 $30.5 a % Growth 18% n 25% Net income / (loss) ($12.6) ($14.7) EBITDA” ($4.7) ($8.8) Memo: R&D $28 $7.6 | $6.7 $5.9 Q2 2019 $7.3 2020e"9) $5.0 Strong YOY double digit revenue growth through 2019; resilient reven

  24. Slide 24: LENSAR COVID Update

    LENSAR COVID Updat aaa ) Key Commentary: Revenue YoY Growth, + In Q4, US performed well until March; Asia impacted the most us 17.8% (38.9%) Asia” a (53.696) (25.9%) + In Q2, US hit hardest, albeit less impacted than A: Ql, and Asia Germany/Other! (9.736) (18.9%) began to return Total (11.599) (31.2

  25. Slide 25: Significant Opportunity to Expand Footprint by Increasing Commercial Infrastructure

    Significant Opportunity to Expand Footprint by Increasing Commercial Infrastructure LENSAR Installed Base by Country Key Commercial Details Global Installed Base: 216 Service engineers: 6 (CA, FL, IL, NJ, TX, Wi) Us Sales Reps: = 3 asof Dec. 2019 (IL, TX, VA) — 62)as of Jan. 2020 (FL, IL, IN, TX, VA

  26. Slide 26: LENSAR's Leadership has Deep Expertise in Cataract Surgery

    LENSAR’s Leadership has Deep Expertise in Cataract Surgery and Device Development and Commercialization Management Nicholas Curtis Alan Connaughton Thomas Staab Chief Executive Officer Chief Operating Officer Chief Financial Officer Previous Experience: Previous Experience: Previous Experience: Wave

  27. Slide 27: Investment Highlights

    Investment Highlights * Established innovation leader with highly respected leadership team and board of directors * Disruptive technology platform with Streamline® IV; developing next-generation workstation with ALLY™ — Streamline® IV - enables optimal treatment of tissue-specific cataract and mana

  28. Slide 28: Appendix

    APPENDIX

  29. Slide 29: Broad and Deep Intellectual Property Portfolio

    Broad and Deep Intellectual Property Portfolio LENSAR Augmented Reality platform, fragmentation, patient interface fully covered * Royalty-free licenses for blocking patents * Issued patents: 29 U.S. and 69 foreign as of June 16, 2020 * Pending patents: 26 pending U.S., 30 pending foreign and one pe

  30. Slide 30: EBITDA Calculation

    EBITDA Calculation $ in 000s 2018 2019 Net Income / (Loss) ($12,593) ($14,657) Plus: Income tax expense 20 0 Less: Other income, net (64) (58) Plus: Interest expense 3,321 2,001 Plus: Depreciation 3,453 2,639 Plus: Amortization of intangible assets 1,137 1,227 EBITDA ($4,726) ($8,848) 30

PDL Biopharma — Investor Presentation (July 2020) on 6ix